Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis

Chien Sheng Wu, Chung Yi Hu, Huei-Fang Tsai, I. Tsu Chyuan, Cheng Ju Chan, Sheng Kai Chang, Ping Ning Hsu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Growth arrest-specific protein 6 (Gas6) is a serum protein involved in granulocyte, platelet and endothelium interaction, and is implicated in both anti-inflammatory response as well as platelet/leukocytes activation. We investigated serum Gas6 level in different clinical manifestations of systemic lupus erythematosus (SLE). Data were collected in 83 patients with SLE and 40 non-lupus controls. The Gas6 levels were detected by enzyme-linked immunosorbent assay. Our results demonstrated that the Gas6 level was higher in SLE patients as compared to the non-lupus control subjects (SLE vs. non-lupus control, median [inter-quartile range (IQR)] 22.67 [19.40-28.60] vs. 18.97 [16.05-20.62] ng/mL, p <0.01). Furthermore, Gas6 level was higher in patients with nephritis (nephritis vs. non-nephritis, median [IQR] 26.21 [21.17-31.61] vs. 22.22 [18.98-26.98] ng/mL, p = 0.03) and in patients with cutaneous vasculitis (vasculitis vs. non-vasculitis, median [IQR] 27.89 [23.24-34.26] vs. 22.30 [19.32-27.16] ng/mL, p = 0.03). Our results indicate that the serum Gas6 level is increased in SLE patients with lupus nephritis or cutaneous vasculitis, implicating a potential to serve as a SLE disease activity marker.

Original languageEnglish
Pages (from-to)625-629
Number of pages5
JournalRheumatology International
Volume34
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Nephritis
Vasculitis
Systemic Lupus Erythematosus
Skin
Serum
Lupus Nephritis
Platelet Activation
Granulocytes
Endothelium
growth arrest-specific protein 6
Blood Proteins
Leukocytes
Anti-Inflammatory Agents
Blood Platelets
Enzyme-Linked Immunosorbent Assay

Keywords

  • Growth arrest-specific protein 6 (Gas6)
  • Nephritis
  • Systemic lupus erythematosus
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis. / Wu, Chien Sheng; Hu, Chung Yi; Tsai, Huei-Fang; Chyuan, I. Tsu; Chan, Cheng Ju; Chang, Sheng Kai; Hsu, Ping Ning.

In: Rheumatology International, Vol. 34, No. 5, 2014, p. 625-629.

Research output: Contribution to journalArticle

Wu, Chien Sheng ; Hu, Chung Yi ; Tsai, Huei-Fang ; Chyuan, I. Tsu ; Chan, Cheng Ju ; Chang, Sheng Kai ; Hsu, Ping Ning. / Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis. In: Rheumatology International. 2014 ; Vol. 34, No. 5. pp. 625-629.
@article{2fcbd12806504ab59f63c4e68d536a64,
title = "Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis",
abstract = "Growth arrest-specific protein 6 (Gas6) is a serum protein involved in granulocyte, platelet and endothelium interaction, and is implicated in both anti-inflammatory response as well as platelet/leukocytes activation. We investigated serum Gas6 level in different clinical manifestations of systemic lupus erythematosus (SLE). Data were collected in 83 patients with SLE and 40 non-lupus controls. The Gas6 levels were detected by enzyme-linked immunosorbent assay. Our results demonstrated that the Gas6 level was higher in SLE patients as compared to the non-lupus control subjects (SLE vs. non-lupus control, median [inter-quartile range (IQR)] 22.67 [19.40-28.60] vs. 18.97 [16.05-20.62] ng/mL, p <0.01). Furthermore, Gas6 level was higher in patients with nephritis (nephritis vs. non-nephritis, median [IQR] 26.21 [21.17-31.61] vs. 22.22 [18.98-26.98] ng/mL, p = 0.03) and in patients with cutaneous vasculitis (vasculitis vs. non-vasculitis, median [IQR] 27.89 [23.24-34.26] vs. 22.30 [19.32-27.16] ng/mL, p = 0.03). Our results indicate that the serum Gas6 level is increased in SLE patients with lupus nephritis or cutaneous vasculitis, implicating a potential to serve as a SLE disease activity marker.",
keywords = "Growth arrest-specific protein 6 (Gas6), Nephritis, Systemic lupus erythematosus, Vasculitis",
author = "Wu, {Chien Sheng} and Hu, {Chung Yi} and Huei-Fang Tsai and Chyuan, {I. Tsu} and Chan, {Cheng Ju} and Chang, {Sheng Kai} and Hsu, {Ping Ning}",
year = "2014",
doi = "10.1007/s00296-013-2882-1",
language = "English",
volume = "34",
pages = "625--629",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis

AU - Wu, Chien Sheng

AU - Hu, Chung Yi

AU - Tsai, Huei-Fang

AU - Chyuan, I. Tsu

AU - Chan, Cheng Ju

AU - Chang, Sheng Kai

AU - Hsu, Ping Ning

PY - 2014

Y1 - 2014

N2 - Growth arrest-specific protein 6 (Gas6) is a serum protein involved in granulocyte, platelet and endothelium interaction, and is implicated in both anti-inflammatory response as well as platelet/leukocytes activation. We investigated serum Gas6 level in different clinical manifestations of systemic lupus erythematosus (SLE). Data were collected in 83 patients with SLE and 40 non-lupus controls. The Gas6 levels were detected by enzyme-linked immunosorbent assay. Our results demonstrated that the Gas6 level was higher in SLE patients as compared to the non-lupus control subjects (SLE vs. non-lupus control, median [inter-quartile range (IQR)] 22.67 [19.40-28.60] vs. 18.97 [16.05-20.62] ng/mL, p <0.01). Furthermore, Gas6 level was higher in patients with nephritis (nephritis vs. non-nephritis, median [IQR] 26.21 [21.17-31.61] vs. 22.22 [18.98-26.98] ng/mL, p = 0.03) and in patients with cutaneous vasculitis (vasculitis vs. non-vasculitis, median [IQR] 27.89 [23.24-34.26] vs. 22.30 [19.32-27.16] ng/mL, p = 0.03). Our results indicate that the serum Gas6 level is increased in SLE patients with lupus nephritis or cutaneous vasculitis, implicating a potential to serve as a SLE disease activity marker.

AB - Growth arrest-specific protein 6 (Gas6) is a serum protein involved in granulocyte, platelet and endothelium interaction, and is implicated in both anti-inflammatory response as well as platelet/leukocytes activation. We investigated serum Gas6 level in different clinical manifestations of systemic lupus erythematosus (SLE). Data were collected in 83 patients with SLE and 40 non-lupus controls. The Gas6 levels were detected by enzyme-linked immunosorbent assay. Our results demonstrated that the Gas6 level was higher in SLE patients as compared to the non-lupus control subjects (SLE vs. non-lupus control, median [inter-quartile range (IQR)] 22.67 [19.40-28.60] vs. 18.97 [16.05-20.62] ng/mL, p <0.01). Furthermore, Gas6 level was higher in patients with nephritis (nephritis vs. non-nephritis, median [IQR] 26.21 [21.17-31.61] vs. 22.22 [18.98-26.98] ng/mL, p = 0.03) and in patients with cutaneous vasculitis (vasculitis vs. non-vasculitis, median [IQR] 27.89 [23.24-34.26] vs. 22.30 [19.32-27.16] ng/mL, p = 0.03). Our results indicate that the serum Gas6 level is increased in SLE patients with lupus nephritis or cutaneous vasculitis, implicating a potential to serve as a SLE disease activity marker.

KW - Growth arrest-specific protein 6 (Gas6)

KW - Nephritis

KW - Systemic lupus erythematosus

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84901341505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901341505&partnerID=8YFLogxK

U2 - 10.1007/s00296-013-2882-1

DO - 10.1007/s00296-013-2882-1

M3 - Article

VL - 34

SP - 625

EP - 629

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 5

ER -